Gelesis said today that it received a $10.6 million (EU €9.4 million) grant to support the manufacturing of its Plenity weight loss device. The Boston-based company said it received the grant from the Puglia Region of Italy, where its material science R&D and clinical supply manufacturing is located. Funds from the grant came from the […]
BaroNova wins FDA nod for TransPyloric Shuttle weight loss device
BaroNova said today that it won FDA approval for its TransPyloric Shuttle non-surgical device intended for treating obesity, now cleared as a weight loss solution for adults with obesity and a body mass index of 30 to 40 kg/m2. The San Carlos, Calif.-based company said that the device is approved for up to 12 months […]
FDA clears Gelesis weight-loss hydrogel pill Plenity
Gelesis (Boston) recently announced that it has received FDA clearance for its Plenity weight management prescription drug. The drug is a weight management aid for adults who have a body mass index of 25-40 kg/m2 and is supposed to be used with diet and exercise. It can be used in people with and without […]
Obalon taps Cowen to explore ‘strategic alternatives’
Obalon Therapeutics (NSDQ:OBLN) today tapped an advisory firm to explore “strategic alternatives,” a week after revealing plans to cut its workforce in half. The Carlsbad, Calif.-based company, which makes a gas-filled balloon designed to treat obesity, said April 3 that it would lay off 49 of its 100 employees, including all of its direct sales force, […]
Epitomee Medical raises $8m for novel weight-loss device
Early-stage medical device developer Epitomee Medical said today that it raised $8 million in a new round of equity financing to support its novel Epitomee Capsule “shapeshifting” pill intended to prevent diabetes and promote weight loss. The Israel-based company said that its Epitomee Capsule contains a shape-shifting scaffold that, after it is ingested, helps the […]
J&J’s Ethicon touts economic study of magnetic Torax GERD device
Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon touted a study showing that the Linx device it acquired two years ago was cheaper than laparoscopic Nissen fundoplication in treating gastrointestinal reflux disease. Shoreview, Minn.-based Torax Medical makes the Linx device, an implant of interlinked titanium beads with magnetic cores designed to augment the esophageal sphincter to prevent […]
Obalon to lay off half its workforce in retail pivot
Obalon Therapeutics (NSDQ:OBLN) said today that it’s planning to lay off 50% of its employees, including all of its direct sales force, in a pivot toward retail. The Carlsbad, Calif.-based company, which makes a gas-filled balloon designed to treat obesity, said it hopes to cut its expenses by 35% during the second quarter after one-time […]
Apollo Endosurgery touts results of stomach-stapling study
Apollo Endosurgery (NSDQ:APEN) has reported key data from 1,000 patients who underwent endoscopic gastroplasty using the company’s OverStitch device. Published in the journal Gastrointestinal Endoscopy, the data include a mean total weight loss of 14.8%±8.5% at 18 months. Three months following surgery, the impact on obesity-related comorbidities included the complete remission of: 13 of 17 cases […]
GI Dynamics wins IRB approval for pivotal U.S. EndoBarrier trial
GI Dynamics (ASX:GID) said yesterday it won Institutional Review Board approval to launch a pivotal trial of its EndoBarrier device exploring its ability to treat diabetes and obesity. The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the intestinal tract to treat type […]
Obalon plunges on trimmed 2018 sales guidance
Obalon Therapeutics (NSDQ:OBLN) shares took a big hit yesterday and continued their slide today after the weight loss balloon maker said it expected to hit the low end of its 2018 sales guidance. Carlsbad, Calif.-based Obalon said last year’s revenues are headed toward the low end of its prior outlook for $9.0 million to $9.9 […]
Obalon lands $30m in capital from new deals
Obalon Therapeutics (NSDQ:OBLN) said this week that it inked two financing deals that could provide the company with up to $30 million in capital. The San Diego, Calif.-based company sells the only FDA-approved, swallowable intragastric balloon system for the treatment of obesity. In one deal, Obalon entered a common stock purchase agreement with Chicago-based institutional investor […]
- 1
- 2
- 3
- …
- 19
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube